Dawg,so let's assume Morrissey and Gisela learned their lesson and set a lower bar for success in Meteor and Celestial, do you put a 50% chance of success on these trials or higher? Secondly , what do you think of kwasmis' warning that 60mg is too low a dosage for cabo to succeed?
The MM must have been putting that trade together for the last minute since early this morning. It looked to me like over 5 million shares traded at the close. The MM must have put together a major short with an institution that desperately wanted out before they had to report their year-end positions.
I agree that there is a great deal of manipulation going on but how do you keep it down and cover shorts at the same time? I still believe there is a great deal of shorting and tax loss selling going on and the volume has not reflected any covering yet (we're only .10 off the lows for the year).
If it pops it won't be until the last week of the year and the first week of next year. The cobi NDA filing was the last potential catalyst we're going to get here for a while, which really didn't help as too many biotech investors have given up on EXEL. It's nice to see Papa and Scangos still holding, but it would be even nicer to see some open market purchases by insiders.
Still long and strong, added a little yesterday, for the inevitable pop after tax loss selling stops. I'll be checking in occasionally until after the New Year.
Happy Holidays and a Happy New Year!
"Cobimetinib (GDC-0973, XL518) was discovered by Exelixis Inc. and is being developed in collaboration with Exelixis. Cobimetinib is also being investigated in combination with several investigational medicines, including an immunotherapy, in several tumor types such as non-small cell lung cancer, colorectal cancer, triple-negative breast cancer and melanoma."
Do you really believe Roche would allow anyone else to buy EXEL? Upgrades will be forthcoming shortly and short covering will commence forthwith.
To be replaced by head of small molecule drug discovery research unit.
I have no idea if this has any implications for EXEL, but the NDA filing for the vemurafenib/cobimentinb combo filing is supposed to be made before end of year according to Roche. Hopefully this will speed things along.
I know I'm not wilder but let me take a shot here.
NSCLC patients primarily experience resistance to erlotinib (Tarceva) within 8 to 12 months of first treatment. Combination therapy will probably be the most promising approach to this resistance. Cabo is one of the TKI's that is being tested in combination with erlotinib to ovecome the over expression of MET which seems to be implicated in the build up of resistance to erlotinib. On clinical trials.gov there have been no updates but in another web site I thought I saw a completion date of July 2015.
A positive outcome (w/PFS as the primary objective, & OS as secondary) would probably be very good for the share price since Genentech(Roche) pioneered erlotinib with OSI Pharmaceuticals (now owned by Astellas of Japan).
I hope that helps.
Your silence in the face of this latest failure speaks volumes. If you've had enough and your out, say so. If you're still hanging in there (as am I), let us know why.
Why am I hanging in there? Ignorance, stubbornness and hopefulness for myself and others suffering from cancer, all of which are not scientific, which is why it would be nice to hear from you guys and your valued scientific knowledge. Thanks in advance.
Zacks releases a PR with negative headline @1:29PM and Piper conference started at exactly 1:30 PM. I have never experienced such a blatant, deliberate and transparent MANIPULATION of any stock like this before. It's not just the shorts or the longs but it's amazing how these events (news releases, brokerage firm updates, holiday surprises etc.) all seem to be coordinated. I haven't bothered with the Piper feed, I can't imagine MMM has anything to add other than "please wait and see". Just sell the frigging company already.
Just like certain baseball players need a change of scenery to get their career going, EXEL needs a new CEO and Gisela has to take responsibility for her design failures and resign as well.
What I'm sayin' Willis, is that in the area of prostate cancer Roche/Genentech doesn't have anything in their pipeline, but it has the resources (financial and intellectual) to put cabo on the right track or maybe even a fast track.
I have no reason to believe that there are any moves in this direction but if Roche wants to be the #1 oncology company they need to address their lack of presence in the prostate market. Buying EXEL would be a way cheaper (not to mention faster) way of solving 2 or 3 holes in their pipeline.
"Inovio Pharmaceuticals, Inc.’s (INO) shares lost 9.7% immediately after the company announced the termination of its collaboration, option and license agreement with Roche Holding (RHHBY) for the co-development of Inovio's prostate cancer candidate, INO-5150."
Take a look at Puma Biotechnology(PBYI) in comparison to EXEL. It recently dropped 10% when it's prime drug candidate neratinib failed to produce any significant improvement in PFS in combination with paclitaxel for HER-2 metastatic breast cancer. This was a P-2 test. PBYI has never had a drug approved, has no income and I'm not even sure they have any P-3 test currently on going.
HOWEVER, PBYI currently sells at a market value of $6.5Billion (with a B). Somebody please tell me what is Puma doing right that EXEL is doing wrong.
I think you guys are referring to different MM's. mj525252 is talking about Morrissey and catfish is talking about market makers.
If Morrissey was fired they better have a replacement who would be recognized by the street. Scangos (Biogen Idec's president) and Papadopolis (Biogen's chairman and still chairman of EXEL in name only) are both graduates of the Exelixis academy of failed but accomplished bosses. EXEL needs to be bought out already but I'm afraid MM (Morrissey) has poisoned the well to the point that a new CEO might be the only solution.
You don't think they could be just softening us up for the Comet-2 disappointment do you? There's always a ying and yang with EXEL, but I really think we are entering a new phase, as we continue to explore the wonders of being the combination drug maker of choice to overcome resistance to first line treatment. GLTA